Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 13, 2021

SELL
$14.69 - $27.52 $450,571 - $844,093
-30,672 Reduced 5.11%
569,328 $15.7 Million
Q1 2021

May 17, 2021

BUY
$16.27 - $41.26 $1.46 Million - $3.71 Million
90,000 Added 17.65%
600,000 $12 Million
Q4 2020

Feb 16, 2021

BUY
$15.96 - $50.0 $1.84 Million - $5.75 Million
115,000 Added 29.11%
510,000 $16.8 Million
Q3 2020

Nov 16, 2020

BUY
$16.77 - $20.65 $6.62 Million - $8.16 Million
395,000 New
395,000 $7.11 Million

Others Institutions Holding INBX

About Inhibrx, Inc.


  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $626M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Farallon Capital Management LLC Portfolio

Follow Farallon Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Farallon Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Farallon Capital Management LLC with notifications on news.